These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Thalassemia major: chelating therapy with deferoxamine]. Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934 [No Abstract] [Full Text] [Related]
3. Improved oxygen delivery to tissues and iron chelator transport through the use of lysed and resealed red blood cells: a new perspective on Cooley's anemia therapy. Ropars C; Teisseire B; Avenard G; Chassaigne M; Hurel C; Girot R; Nicolau C Ann N Y Acad Sci; 1985; 445():304-15. PubMed ID: 3860134 [No Abstract] [Full Text] [Related]
4. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography. Flynn DM; Hoffbrand AV; Politis D Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017 [No Abstract] [Full Text] [Related]
6. Iron overload: pathogenesis and treatment with chelating agents. Huebers H Blut; 1983 Aug; 47(2):61-7. PubMed ID: 6871476 [No Abstract] [Full Text] [Related]
7. Reduction of iron overload in thalassemia. Piomelli S; Graziano J Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742 [No Abstract] [Full Text] [Related]
8. Thalassemia in Britain and Australia. Modell B; Matthews R Birth Defects Orig Artic Ser; 1976; 12(8):13-29. PubMed ID: 795477 [No Abstract] [Full Text] [Related]
9. Treatment of iron overload in Cooley's anemia. Cohen A; Mizanin J; Schwartz E Ann N Y Acad Sci; 1985; 445():274-81. PubMed ID: 3860130 [No Abstract] [Full Text] [Related]
10. Iron excretion in thalassemia after the administration of chelating agents. Markum AH; Iskandar W; Keng KL; Odang O Paediatr Indones; 1969; 9(3):89-98. PubMed ID: 4981722 [No Abstract] [Full Text] [Related]
11. Recognition and treatment of iron overload. Brown EB Adv Intern Med; 1980; 26():159-86. PubMed ID: 7013439 [No Abstract] [Full Text] [Related]
12. Iron chelation. Hershko C; Link G; Pinson A Prog Clin Biol Res; 1989; 309():133-40. PubMed ID: 2675082 [No Abstract] [Full Text] [Related]
13. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547 [TBL] [Abstract][Full Text] [Related]
14. Current concepts in the overall management of thalassemia. Propper RD Ann N Y Acad Sci; 1980; 344():375-83. PubMed ID: 6930877 [No Abstract] [Full Text] [Related]
15. The effect of treatment with long-term chelating agents on iron overload in thalassaemia. Letsky EA; Flynn DM; Barry M Br J Haematol; 1973 Aug; 25(2):285. PubMed ID: 4726921 [No Abstract] [Full Text] [Related]
16. Combined use of oral chelators and desferrioxamine in thalassemia. Piga A; Roggero S; Marletto F; Sacchetti L; Longo F Hematology; 2005; 10 Suppl 1():89-91. PubMed ID: 16188646 [No Abstract] [Full Text] [Related]
17. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Giardina PJ; Grady RW Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288 [TBL] [Abstract][Full Text] [Related]
18. A controlled trial of long-term chelation therapy in homozygous beta-thalassemia. Letsky EA Birth Defects Orig Artic Ser; 1976; 12(8):31-41. PubMed ID: 1009233 [No Abstract] [Full Text] [Related]
19. [Hypertransfusion, chelating and immunocorrective therapy in beta-thalassemia major]. Zeĭnalova AA; Ragimov AA; Dashkova NG; Mamedova FR; Kurbanova SA Pediatriia; 1987; (2):55-60. PubMed ID: 3575062 [No Abstract] [Full Text] [Related]
20. [Current treatment of thalassemia major in children]. Lévy G; Bost M Pediatrie; 1980; 35(5):451-5. PubMed ID: 7422454 [No Abstract] [Full Text] [Related] [Next] [New Search]